MarginsXMarginsX
Home › Markets › Health Care › IMNM

Immunome Inc. (IMNM)

IMNM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$17.61
-6.18% on the day
Market cap
$2.1B
Mid cap
Revenue · 2025
$6.9M
-23.2% on 2024
Net income · 2025
-$212.4M
-3060.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/0001193125-26-088172-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerIMNM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001472012
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$6.9M
Net income-$212.4M
Operating income-$224.1M
Net margin-3060.0%
Operating margin-3228.8%
Revenue growth-23.2%
Cash$653.5M
Total assets$683.2M
P/E (computed)Net income was not positive
P/S (computed)299.6×

Warning signs

Cash runway
11.2 months
$212.8M cash at September 30, 2026
Share count, 1 year
+28.7%
2025-11-03 to 2026-11-04 · +176.3% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$25.2M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$212.8M cash; operating cash flow -$57.3M a quarter.Report 2026-09-30
Shares outstanding118,072,943 (2026-11-04); 91,710,277 a year earlier; 42,729,847 three years earlier.Cover page 2026-11-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2025-12-17
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-03-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $2.3M, sold $27.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$85.8M-$60.8M$212.8MNo debt tags$010-Q 2026-11-09
Q2 2026
2026-06-30
$0-$73.1M-$61.7M$217.7MNo debt tags$010-Q 2026-08-11
Q1 2026
2026-03-31
$0-$53.8M-$58.6M$582.7MNo debt tags$4.0M10-Q 2026-05-12
Q4 2025
2025-12-31
$0-$69.9M-$48.0M$653.5MNo debt tags$6.9M10-K 2026-03-03
Q3 2025
2025-09-30
$0-$57.5M-$40.5M$272.6MNo debt tags$9.7M10-Q 2026-11-09
Q2 2025
2025-06-30
$4.0M-$43.4M-$49.4M$143.9MNo debt tags$12.6M10-Q 2026-08-11
Q1 2025
2025-03-31
$2.9M-$41.6M-$53.1M$257.6MNo debt tags$10.9M10-Q 2026-05-12
Q4 2024
2024-12-31
$2.7M-$80.2M-$42.1M$143.4MNo debt tags$9.0M10-K 2026-03-03

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-11-09
Latest annual report10-K2026-03-03
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 465 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.3%
1 month+6.8%
3 months-29.0%
Year to date-12.6%
1 year+13.7%
From 52-week high-37.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
AUPHAurinia Pharmaceuticals Inc$15.48-1.59%$2.1B
BHVNBiohaven Ltd. Common Shares$13.80-0.14%$2.1B
SDGRSchrodinger Inc.$27.36-7.35%$2.1B
PVLAPalvella Therapeutics Inc.$144.60-5.17%$2.1B
SEPNSepterna Inc.$41.67-2.18%$2.0B
TRAXFirst Tracks Biotherapeutics Inc. Ordinary Shares$46.56-1.15%$2.0B
VERAVera Therapeutics Inc.$26.97-4.02%$1.9B
HRMYHarmony Biosciences Holdings Inc.$32.96-2.37%$1.9B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier